Otsikko |
Lataa koko teksti |
---|
21.12.2020
Servier to Acquire Agios Pharmaceuticals' Oncology Business
|
 |
04.06.2020
Servier completes the acqusition of Symphogen
completes the acquisition ofServier completes the acquisition of Symphogen |
 |
19.03.2020
Coronavirus Information (COVID-19)
|
 |
21.10.2018
Servier and Taiho Oncology Announce Positive Results from TAGS presented at ESMO 2018
|
 |
16.10.2018
2018 Pasteur-Weizmann/Servier-Price awarded to Professor Michel Sadelain
|
 |
19.9.2018
September is Blood Cancer & Childhood Cancer Awareness Month
|
 |
31.8.2018
Servier finalizes acquisition of Shire's oncology branch
|
 |
26.6.2018
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis patients
|
 |
23.6.2018
New data for trifluridine/tipiracil(LONSURF) in metastatic colorectal cancer presented at ESMO's World Congress on Gastrointestinal Cancer
|
 |
3.4.2018
Servier and Scandicure enter into agreement to conduct research in the field of metabolic diseases
|
 |
13.3.2018
WeHealth by Servier and DEEPLINK MEDICAL sign a partnership to develop a new e-health solution in the field of oncology
|
 |
4.1.2018
Servier and Treventis begins strategic research partnership in degenerative diseases
|
 |
13.12.2017
Preliminary data from Servier and Pfizer's UCART 19 product candidate shows high complete remission rate across two Phase I adult and periatric acute lymphoblastic leukemia trials
|
 |
02.11.2017
Servier and Pfizer announce preliminary results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th ASH Annual Meeting
|
 |
19.10.2017
Servier establishes strategic research alliance with Harvard University
|
 |
29.6.2017
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T
|
 |
3.5..2017
Servier and miRagen extend collaboration for the research, developmant and commercialization of microRNA-targeting therapeutics
|
 |
26.4.2017
Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration
|
 |
25.4.2017
Servier and CTI BioPharma expand licence and collaboration agreemant to develop and commercialize Pixuvri
|
 |
14.3.2017
Servier and Neurochlore join forces to treat autism in children
|
 |
28.12.2017
OSE immunotherapeutics and Servier, partnership agreement to develop and commercialise OSE immunotherapeutics' Effi-7, an antagonist of the interleukin-7 receptor.
|
 |
20.10.2016
New compound shows promise in treating multiple human cancers
|
 |
23.6.2015
Ivabradiini (Procoralan) rajoitetusti erityiskorvattavaksi 1.7.2015 lähtien
|
 |
16.6.2015
Taiho Pharmaceutical Co., Ltd. and Servier Enter into a Licence Agreement for Development and Commercialization of an oral Anticancer Drug in Europe
|
 |
17.4.2015
FDA approves ivabradine for patients with chronic heart failure
|
 |
12.11.2014
Intarcia and Servier sign ex-U.S. partnership for ITCA 650 in diabetes;Intarcia retains independence & full control in the U.S. & Japan
|
 |
2.10.2014
Servier new reasearch partnership with the Walter and Eliza Hall Institute to target Achilles' heel of many cancers
|
 |
26.9.2014
EMA Confirms positive benefit-risk for antidepressant Valdoxan/Thymanax (agomelatine)
|
 |